The Optimized Lipid-Modified Prodrug for CNV Treatment

Area of Science:

• Ophthalmology
• Nanomedicine
• Drug Delivery Systems

Background:

• Choroidal neovascularization (CNV) is a major cause of vision loss.
• Current anti-vascular endothelial growth factor treatments for CNV have limitations including poor compliance, high cost, and variable efficacy.
• Novel therapeutic strategies are needed to improve treatment outcomes for CNV.

Purpose of the Study:

• To synthesize and evaluate novel lipid-modified prodrugs of SU5402 (SU) for improved anti-neovascularization effects.
• To develop nanoformulations of these prodrugs using polyvinyl alcohol (PVA) as a stabilizer.
• To assess the efficacy of these nanoformulations in treating CNV in a preclinical model.

Main Methods:

• Synthesis of SU5402 prodrugs with varying lipid chain lengths (C12, C16, C20, C24, C28).
• Preparation of nanoformulations (NPs) using 1% PVA.
• Evaluation of drug retention, tissue permeability (endocytosis/exocytosis), and anti-CNV efficacy in a mouse model.

Main Results:

• SU-C20 NPs demonstrated significantly prolonged drug retention in the eye (up to 70 days).
• SU-C20 NPs exhibited enhanced tissue permeability.
• In CNV mice, SU-C20 NPs reduced fundus leakage intensity by 42.5% and area by 51.5%, effectively inhibiting CNV progression.

Conclusions:

• Lipid modification of SU5402 into SU-C20 NPs represents an effective strategy for treating fundus neovascular diseases.
• SU-C20 NPs offer prolonged ocular retention and improved tissue penetration, enhancing therapeutic efficacy.
• This approach provides a promising alternative therapy for wet age-related macular degeneration (wAMD).